Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 4/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387631 | 0.87 | LRRK2 (0.62) | LRRK2MET | |
| SCHEMBL2388522 | 0.83 | LRRK2 (0.60) | LRRK2GRK5METHRH3JAK2 | |
| SCHEMBL2386770 | 0.83 | LRRK2 (0.60) | LRRK2GRK5METHRH3JAK2 | |
| SCHEMBL2387184 | 0.83 | LRRK2 (0.53) | LRRK2GRK5MET | |
| SCHEMBL2386093 | 0.83 | MET (0.53) | GRK5MET | |
| SCHEMBL2388959 | 0.82 | LRRK2 (0.52) | LRRK2GRK5METHRH3 | |
| SCHEMBL2383649 | 0.81 | KCNH2 (0.58) | LRRK2GRK5METJAK2TGFBR1 | |
| SCHEMBL2388193 | 0.80 | FYN (0.51) | LRRK2GRK5METPIK3CDFYN | |
| SCHEMBL2386713 | 0.79 | MET (0.49) | LRRK2GRK5METTGFBR1 | |
| SCHEMBL2388009 | 0.78 | MET (0.55) | GRK5METFYNTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | LRRK2 1684/4885GRK5 579/4885MET 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.